Hui Feng

Active 1997–2026

579
Papers
36,265
Citations
96
h-index
388
i10-index

Citations

Citations per year for Hui Feng1996: 1 citations1998: 2 citations1999: 1 citations2000: 5 citations2001: 6 citations2002: 7 citations2003: 13 citations2004: 28 citations2005: 18 citations2006: 35 citations2007: 25 citations2008: 30 citations2009: 28 citations2010: 47 citations2011: 69 citations2012: 67 citations2013: 80 citations2014: 134 citations2015: 184 citations2016: 250 citations2017: 299 citations2018: 340 citations2019: 754 citations2020: 1,225 citations2021: 1,571 citations2022: 1,434 citations2023: 1,191 citations2024: 2,007 citations2025: 1,103 citations2026: 116 citations1997: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorChina: 5,144 citing papers, 35.3% of this breakdownUnited States: 2,314 citing papers, 15.9% of this breakdownUnited Kingdom: 540 citing papers, 3.7% of this breakdownIndia: 472 citing papers, 3.2% of this breakdownGermany: 441 citing papers, 3% of this breakdownItaly: 359 citing papers, 2.5% of this breakdownAustralia: 353 citing papers, 2.4% of this breakdownCanada: 342 citing papers, 2.3% of this breakdownJapan: 302 citing papers, 2.1% of this breakdownFrance: 301 citing papers, 2.1% of this breakdownSouth Korea: 301 citing papers, 2.1% of this breakdownSpain: 230 citing papers, 1.6% of this breakdown
0%35.3%Other 23.8%

Fields

  • Medicine34.5%
  • Biochemistry, Genetics and Molecular Biology21.7%
  • Computer Science10.3%
  • Engineering8.9%
  • Materials Science8.1%
  • Agricultural and Biological Sciences4%
  • Other12.5%

Topics

  • SARS-CoV-2 and COVID-19 Research2.6%
  • Cancer Immunotherapy and Biomarkers2%
  • Advanced biosensing and bioanalysis techniques2%
  • Carbon and Quantum Dots Applications1.7%
  • Monoclonal and Polyclonal Antibodies Research1.3%
  • COVID-19 Clinical Research Studies1.2%
  • Other89.2%

Coauthors

All papers

Open in search
  1. MemSeg: A semi-supervised method for image surface defect detection using differences and commonalities

    Authors: , , - Engineering Applications of Artificial Intelligence, Eng. Appl. Artif. Intell. 2023 cited by 227

  2. Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Zhanhui Miao, Meili Sun, Conghua Xie, Ying Liu, Qifeng Wang, Lina Zhao, Qi Li, Canhong Huang, Ke Jiang, Kunyu Yang, Daojun Li, Yunpeng Liu, Zhitu Zhu, Rixin Chen, Liqun Jia, Wei Li, Wangjun Liao, Hongxu Liu, Daiyuan Ma, Jie Ma, Yanru Qin, Zhihong Shi, Qichun Wei, Ke Xiao, Yan Zhang, Ying Zhang, Xin Chen, Guanghai Dai, Jianxing He, Junhe Li, Guanghui Li, Yong Liu, Zhihua Liu, Xianglin Yuan, Junping Zhang, Zhichao Fu, Yifu He, Fang Ju, Zheng Liu, Peng Tang, Tiejun Wang, Weibo Wang, Jing Zhang, Xianming Luo, Xiongwen Tang, Rena May, Hui Feng, Sheng Yao, Patricia Keegan, Rui‐Hua Xu, Feng Wang - Cancer Cell 2022 cited by 565

  3. Crop Phenomics and High-Throughput Phenotyping: Past Decades, Current Challenges, and Future Perspectives

    Authors: , , , , , , , - Molecular Plant 2020 cited by 914

  4. A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature 2020 cited by 1,499

  5. Toripalimab or placebo plus chemotherapy as first-line treatment in advanced nasopharyngeal carcinoma: a multicenter randomized phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Muh‐Hwa Yang, Chia-Jui Yen, Jens Samol, Hui Feng, Sheng Yao, Patricia Keegan, Rui‐Hua Xu - Nature Medicine 2021 cited by 403

  6. Efficacy, Safety, and Correlative Biomarkers of Toripalimab in Previously Treated Recurrent or Metastatic Nasopharyngeal Carcinoma: A Phase II Clinical Trial (POLARIS-02)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2021 cited by 351

  7. The emerging role and targetability of the TCA cycle in cancer metabolism

    Authors: , , , - Protein & Cell 2017 cited by 564

  8. Expression, regulation, and function of exosome‐derived miRNAs in cancer progression and therapy

    Authors: , , , - The FASEB Journal 2021 cited by 262

  9. A Biparatopic HER2-Targeting Antibody-Drug Conjugate Induces Tumor Regression in Primary Models Refractory to or Ineligible for HER2-Targeted Therapy

    Authors: , , , , , , , , , , , , , , , , , , , - Cancer Cell 2016 cited by 390

  10. Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Zhuang Yu, Anwen Liu, Xiuwen Wang, Caicun Zhou, Diansheng Zhong, Liyun Miao, Zhihong Zhang, Hui Zhao, Jiaqi Yang, Dong Wang, Yingyi Wang, Qiang Li, Xiaodong Zhang, Mei Ji, Zhenzhou Yang, Jiuwei Cui, Beili Gao, Buhai Wang, Hu Liu, Lei Nie, Mei He, Jin Shi, Wei Gu, Yongqian Shu, Tong Zhou, Jian Feng, Xinmei Yang, Cheng Huang, Bo Zhu, Yu Yao, Xiongwen Tang, Jianjun Yu, Ellen Maher, Hui Feng, Sheng Yao, Patricia Keegan, Jie Wang - Journal of Clinical Oncology 2022 cited by 172

  11. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - Annals of Oncology 2019 cited by 476

  12. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Muh‐Hwa Yang, Chia‐Jui Yen, Jens Samol, Xianming Luo, Xiaojun Wang, Xiongwen Tang, Hui Feng, Sheng Yao, Patricia Keegan, Rui‐Hua Xu - JAMA 2023 cited by 233

  13. Interferon regulatory factor 1 (IRF1) and anti-pathogen innate immune responses

    Authors: , , , , - PLoS Pathogens 2021 cited by 298

  14. Toward Packet Routing With Fully Distributed Multiagent Deep Reinforcement Learning

    Authors: , , , , , - IEEE Transactions on Systems Man and Cybernetics Systems, IEEE Trans. Syst. Man Cybern. Syst. 2020 cited by 99

  15. A Risk Prediction Model Based on Machine Learning for Cognitive Impairment Among Chinese Community-Dwelling Elderly People With Normal Cognition: Development and Validation Study

    Authors: , , , , , - Journal of Medical Internet Research 2021 cited by 132

  16. Estimation of the soil arsenic concentration using a geographically weighted XGBoost model based on hyperspectral data

    Authors: , , , , , , , , - The Science of The Total Environment 2022 cited by 136

  17. Comparative effectiveness of non-pharmacological interventions for frailty: a systematic review and network meta-analysis

    Authors: , , , , , , , , - Age and Ageing 2023 cited by 123

  18. Generation of multicomponent atomic Schrödinger cat states of up to 20 qubits

    Authors: , , , , , , , , , , , , , , , - Science 2019 cited by 367

  19. Glutamine Anabolism Plays a Critical Role in Pancreatic Cancer by Coupling Carbon and Nitrogen Metabolism

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Cell Reports 2019 cited by 195

  20. Licochalcone B specifically inhibits the NLRP3 inflammasome by disrupting NEK7‐NLRP3 interaction

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , - EMBO Reports 2021 cited by 108

  21. Combining high-throughput phenotyping and genome-wide association studies to reveal natural genetic variation in rice

    Authors: , , , , , , , , , , , , , , - Nature Communications 2014 cited by 632

  22. Safety, Efficacy, and Biomarker Analysis of Toripalimab in Previously Treated Advanced Melanoma: Results of the POLARIS-01 Multicenter Phase II Trial

    Authors: , , , , , , , , , , , , , , , - Clinical Cancer Research 2020 cited by 167

  23. Plant-Derived Exosome-Like Nanoparticles: Emerging Nanosystems for Enhanced Tissue Engineering

    Authors: , , , , , , , - International Journal of Nanomedicine 2024 cited by 56

  24. Effectiveness of Exergaming in Improving Cognitive and Physical Function in People With Mild Cognitive Impairment or Dementia: Systematic Review

    Authors: , , , , , , , , , - JMIR Serious Games 2020 cited by 135